FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2617505053> ?p ?o ?g. }

• W2617505053 endingPage "3542" @default.
• W2617505053 startingPage "3542" @default.
• W2617505053 abstract "Abstract Background: Patient (Pt) outcomes have improved significantly in multiple myeloma (MM) due to widespread use of novel therapeutic agents and stem cell transplant (SCT) butoutcome disparities among racial/ethnic groups exist. Differences in access to and utilization of novel therapeutics are likely contributing factors. We performed an analysis of the SEER-Medicare database to explore such differences. Methods: Pts with a confirmed MM diagnosis between 2007-2009 and continuous Medicare coverage from 1 year prior to diagnosis through end of 2012 were included. Medicare Part D data (oral medications) is not available prior to 2007 so utilization analysis of lenalidomide (LEN), thalidomide (THAL) and bortezomib (BORT) was performed from 2007-2009. Demographic/survival data (PEDSAF files) and drug/SCT utilization (NCH, OUTSAF, PDESAF files) were obtained (HCPCS/NCH codes). Categorical and continuous variables were compared using /Fisher tests and Wilcoxon tests, respectively. Gender, age, and year-adjusted p-values were calculated using logistic regression. A proportional odds model was used to detect time-dependent trends in drug usage within 12 months of MM diagnosis across year of diagnosis by race. Separate multivariate models were fit for each drug adjusting for gender, age, drug use and race. Associations between drug use and overall survival (OS) were examined using a time dependent proportional hazards model. Results: A total of 5358 MM pts were included (any Medicare claims) with 2733 (51%) males. Mutually exclusive race categories were White (W; 67%), African-American (AA; 18%), Hispanic (H; 10%) and Asian (A; 5%). Median follow up was 2.4 yrs. Baseline pt characteristics were significantly different for age with AA being the youngest at diagnosis (p<0.001) and for gender (p<0.001) with W having the largest (53.4%) and AA the smallest (45.2%) proportion of males. Medicare claims capture only pts without any supplemental insurance and so drug utilization in this database was much lower than expected for all subgroups. Year-wise comparison showed that LEN use within the first year of MM diagnosis increased from 2007 to 2009 (16.5% to 27.7%; p<0.001) and there was a significant decrease in median days to first dose (p=0.002). Over the same period, use of THAL decreased (26.6% to 14.6%; p<0.001) while use of BORT (7.8% to 15.4%; p<0.001), SCT (3.3% to 6.2%; p<0.001) and more than 1 novel agent (2.5% to 5.7%; p<0.001) increased significantly. Utilization patterns within first year of MM diagnosis were significantly different among racial subgroups for LEN, THAL, BORT, SCT and >1 novel agent use. (Figure 1) No significant difference was seen for days to first dose of LEN/THAL for any race but for BORT, H got first dose in median 117 days after diagnosis as compared to median 46-51 days for other races (p=0.025). During the first year after diagnosis, W and AA had higher BORT only usage while H and A had a higher LEN/THAL only usage (p<0.001). For drug use by year and race, a significant increase in LEN use was seen from 2007 to 2009 in W (p<0.001), AA (p=0.001) and A (p<0.001) but not H (p=0.26) while THAL use decreased significantly for all races. BORT use increased significantly for all except A (p=0.602) and SCT use increased significantly for all except AA (p=0.068). Inferior OS was significantly associated with older age (p<0.001) and males (p<0.001). LEN/THAL use within the first year of diagnosis did not affect OS while BORT use within the first year of diagnosis increased mortality risk (HR 1.18, p=0.021). SCT use improved OS (HR 0.52, p<0.001). Conclusions: In this comprehensive analysis of MM therapeutics utilization, we noted significant variability among different racial groups. The use of LEN, BORT and SCT has increased while THAL has decreased over time but disparities exist in utilization among different races, with lower use of LEN in AA, lower use of BORT in A and significantly delayed use of BORT in H, which are all notable since racial/ethnic minorities are fast growing in the US population mix and seem to have inequitable utilization and/or access. Inferior survival with early BORT use may represent selection bias of pts with more advanced/aggressive disease. These trends need to be examined in larger sample sizes especially from commercial payers to eliminate drug access and utilization disparities and achieve equitable benefit of therapeutic advances across all racial subgroups. Figure 1 Figure 1. Figure 2 Figure 2. Disclosures Ailawadhi: Pharmacyclics: Consultancy; Novartis: Consultancy; Amgen Inc: Consultancy; Takeda Oncology: Consultancy." @default.
• W2617505053 created "2017-06-05" @default.
• W2617505053 creator A5008837356 @default.
• W2617505053 creator A5010286156 @default.
• W2617505053 creator A5012173490 @default.
• W2617505053 creator A5018113870 @default.
• W2617505053 creator A5043033429 @default.
• W2617505053 creator A5043116502 @default.
• W2617505053 creator A5044589378 @default.
• W2617505053 creator A5045985079 @default.
• W2617505053 creator A5056714061 @default.
• W2617505053 creator A5057155689 @default.
• W2617505053 creator A5058557833 @default.
• W2617505053 creator A5062040108 @default.
• W2617505053 creator A5065788958 @default.
• W2617505053 creator A5091287816 @default.
• W2617505053 date "2016-12-02" @default.
• W2617505053 modified "2023-10-18" @default.
• W2617505053 title "Racial Disparity in Drug Utilization Among Multiple Myeloma Patients: A SEER Medicare Analysis" @default.
• W2617505053 doi "https://doi.org/10.1182/blood.v128.22.3542.3542" @default.
• W2617505053 hasPublicationYear "2016" @default.
• W2617505053 type Work @default.
• W2617505053 sameAs 2617505053 @default.
• W2617505053 citedByCount "1" @default.
• W2617505053 countsByYear W26175050532017 @default.
• W2617505053 crossrefType "journal-article" @default.
• W2617505053 hasAuthorship W2617505053A5008837356 @default.
• W2617505053 hasAuthorship W2617505053A5010286156 @default.
• W2617505053 hasAuthorship W2617505053A5012173490 @default.
• W2617505053 hasAuthorship W2617505053A5018113870 @default.
• W2617505053 hasAuthorship W2617505053A5043033429 @default.
• W2617505053 hasAuthorship W2617505053A5043116502 @default.
• W2617505053 hasAuthorship W2617505053A5044589378 @default.
• W2617505053 hasAuthorship W2617505053A5045985079 @default.
• W2617505053 hasAuthorship W2617505053A5056714061 @default.
• W2617505053 hasAuthorship W2617505053A5057155689 @default.
• W2617505053 hasAuthorship W2617505053A5058557833 @default.
• W2617505053 hasAuthorship W2617505053A5062040108 @default.
• W2617505053 hasAuthorship W2617505053A5065788958 @default.
• W2617505053 hasAuthorship W2617505053A5091287816 @default.
• W2617505053 hasConcept C126322002 @default.
• W2617505053 hasConcept C143998085 @default.
• W2617505053 hasConcept C144024400 @default.
• W2617505053 hasConcept C149923435 @default.
• W2617505053 hasConcept C151956035 @default.
• W2617505053 hasConcept C156957248 @default.
• W2617505053 hasConcept C2776063141 @default.
• W2617505053 hasConcept C2776364478 @default.
• W2617505053 hasConcept C38180746 @default.
• W2617505053 hasConcept C71924100 @default.
• W2617505053 hasConceptScore W2617505053C126322002 @default.
• W2617505053 hasConceptScore W2617505053C143998085 @default.
• W2617505053 hasConceptScore W2617505053C144024400 @default.
• W2617505053 hasConceptScore W2617505053C149923435 @default.
• W2617505053 hasConceptScore W2617505053C151956035 @default.
• W2617505053 hasConceptScore W2617505053C156957248 @default.
• W2617505053 hasConceptScore W2617505053C2776063141 @default.
• W2617505053 hasConceptScore W2617505053C2776364478 @default.
• W2617505053 hasConceptScore W2617505053C38180746 @default.
• W2617505053 hasConceptScore W2617505053C71924100 @default.
• W2617505053 hasIssue "22" @default.
• W2617505053 hasLocation W26175050531 @default.
• W2617505053 hasOpenAccess W2617505053 @default.
• W2617505053 hasPrimaryLocation W26175050531 @default.
• W2617505053 hasRelatedWork W2136773918 @default.
• W2617505053 hasRelatedWork W2344741804 @default.
• W2617505053 hasRelatedWork W3021932827 @default.
• W2617505053 hasRelatedWork W3113412439 @default.
• W2617505053 hasRelatedWork W3116197883 @default.
• W2617505053 hasRelatedWork W3121407702 @default.
• W2617505053 hasRelatedWork W3138975757 @default.
• W2617505053 hasRelatedWork W3185554486 @default.
• W2617505053 hasRelatedWork W4226042254 @default.
• W2617505053 hasRelatedWork W881425895 @default.
• W2617505053 hasVolume "128" @default.
• W2617505053 isParatext "false" @default.
• W2617505053 isRetracted "false" @default.
• W2617505053 magId "2617505053" @default.
• W2617505053 workType "article" @default.